Similar articles

• Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.

  Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA. Laviolette M, et al. J Allergy Clin Immunol. 2013 Nov;132(5):1086-1096.e5. doi: 10.1016/j.jaci.2013.05.020. Epub 2013 Jul 16. J Allergy Clin Immunol. 2013. PMID: 23866823 Free PMC article. Clinical Trial.
• The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.

  Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X. Goldman M, et al. Curr Med Res Opin. 2017 Sep;33(9):1605-1613. doi: 10.1080/03007995.2017.1347091. Epub 2017 Jul 19. Curr Med Res Opin. 2017. PMID: 28644104 Clinical Trial.
• Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.

  Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E. Jackson DJ, et al. Adv Ther. 2020 Feb;37(2):718-729. doi: 10.1007/s12325-019-01191-2. Epub 2019 Dec 14. Adv Ther. 2020. PMID: 31836949 Free PMC article. Clinical Trial.
• Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review.

  Ando K, Tanaka A, Sagara H. Ando K, et al. Int J Mol Sci. 2020 Jan 30;21(3):889. doi: 10.3390/ijms21030889. Int J Mol Sci. 2020. PMID: 32019141 Free PMC article.
• Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.

  Matera MG, Calzetta L, Rinaldi B, Cazzola M. Matera MG, et al. Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):1007-1013. doi: 10.1080/17425255.2017.1359253. Epub 2017 Jul 24. Expert Opin Drug Metab Toxicol. 2017. PMID: 28737051 Review.